Status
Conditions
About
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life.
The investigators expect, that 30-50% of patients will show pharmacon - gene induced weight gain (> 7% of initial bodyweight) while the rest of patients will maintain unaltered bodyweight.
Full description
The primary aim of this study is to investigate status of neuro-and enteroendocrine axes with focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities and inflammations adipokins in patients during treatment with antipsychotics (AP) in relation to weight gain.
The second aim is to evaluate the connection between weight gain and patients´ own perception of their quality of life and health.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
One criteria is sufficient to exclude patients from the study:
100 participants in 2 patient groups
Loading...
Central trial contact
Henrik Lublin, MD DMSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal